Tech and pharma mergers are the next targets for the European Commission after the EU General Court’s affirmation of the Commission’s new referral power under Article 22 EUMR
Since announcing the $8 billion acquisition in September 2020, Illumina, Inc. (hereafter “Illumina”) and Grail, LLC (hereafter “Grail”) have been put through the wringer by the European Commission (hereafter “Commission”). The former is an American healthcare company which developed next-generation sequencing technology to determine the order of the basic building blocks in entire genomes or … Continue reading “Tech and pharma mergers are the next targets for the European Commission after the EU General Court’s affirmation of the Commission’s new referral power under Article 22 EUMR”